{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:25:55Z","timestamp":1789053955153,"version":"build-2803163510"},"reference-count":184,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Adenovirus (AdV) infections can lead to significant morbidity and increased mortality in immunocompromised populations such as hematopoietic stem cell and solid organ transplant recipients. This review evaluates currently available and emerging therapies for AdV infections. Cidofovir, while most commonly used, is limited by its variable efficacy and nephrotoxicity. This led to the development of brincidofovir, which has a better safety profile and great in vitro potency against AdV. The use of ribavirin and ganciclovir has been reported in the literature, but their use is limited due to inconsistent efficacy. Immune-based approaches, such as adoptive T-cell therapy, have shown promise in achieving viral clearance and improving survival but remain constrained by challenges related to manufacturing complexity and risks of graft-versus-host disease. This review underscores the need for standardized treatment protocols as well as comparative studies to identify optimal dosing and timing to initiate treatment. Future research should focus on individualized treatment approaches and the development of novel therapeutic agents to address the unmet clinical needs of AdV management.<\/jats:p>","DOI":"10.3390\/v17050599","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T06:38:37Z","timestamp":1745390317000},"page":"599","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Treating Adenovirus Infection in Transplant Populations: Therapeutic Options Beyond Cidofovir?"],"prefix":"10.3390","volume":"17","author":[{"given":"Niyati","family":"Narsana","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, UC Davis Medical Center, Sacramento, CA 95817, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ha","sequence":"additional","affiliation":[{"name":"Stanford Antimicrobial Safety and Sustainability Program, Stanford Health Care, Stanford, CA 94305, USA"},{"name":"Division of Infectious Diseases & Geographic Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora Y.","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases & Geographic Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3181\/00379727-84-20714","article-title":"Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture","volume":"84","author":"Rowe","year":"1953","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3181\/00379727-85-20825","article-title":"Recovery of new agent from patients with acute respiratory illness","volume":"85","author":"Hilleman","year":"1954","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJM198502283120901","article-title":"Adenovirus infections in patients undergoing bone-marrow transplantation","volume":"312","author":"Shields","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"ref_4","unstructured":"International Committee on Taxonomy of Viruses: ICTV (2025, March 19). Available online: https:\/\/ictv.global\/report\/chapter\/adenoviridae\/adenoviridae."},{"key":"ref_5","unstructured":"(2024, November 25). Available online: http:\/\/hadvwg.gmu.edu."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1128\/JVI.00354-11","article-title":"Using the whole-genome sequence to characterize and name human adenoviruses","volume":"85","author":"Seto","year":"2011","journal-title":"J. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kajon, A.E. (2024). Adenovirus infections: New insights for the clinical laboratory. J. Clin. Microbiol., 62.","DOI":"10.1128\/jcm.00836-22"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.coviro.2011.05.024","article-title":"Viral attachment strategies: The many faces of adenoviruses","volume":"1","author":"Cupelli","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Nesti\u0107, D., Bo\u017einovi\u0107, K., Pehar, I., Wallace, R., Parker, A.L., and Majhen, D. (2021). The Revolving Door of Adenovirus Cell Entry: Not All Pathways Are Equal. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101585"},{"key":"ref_10","unstructured":"Bennett, J.E., Dolin, R., and Blaser, M.J. (2020). Adenoviruses. Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases, Elsevier Inc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/ajh.26723","article-title":"Adenovirus disease after hematopoietic cell transplantation: A Japanese transplant registry analysis","volume":"97","author":"Inamoto","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bbmt.2018.12.753","article-title":"Incidence of Adenovirus Infection in Hematopoietic Stem Cell Transplantation Recipients: Findings from the AdVance Study","volume":"25","author":"Petterson","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e13283","DOI":"10.1111\/tid.13283","article-title":"Practice patterns and incidence of adenovirus infection in allogeneic hematopoietic cell transplant recipients: Multicenter survey of transplant centers in the United States","volume":"22","author":"Papanicolaou","year":"2020","journal-title":"Transpl. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e13527","DOI":"10.1111\/ctr.13527","article-title":"Adenovirus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Florescu","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1586\/14787210.2013.836964","article-title":"Diagnosis and treatment of adenovirus infection in immunocompromised patients","volume":"11","author":"Boztug","year":"2013","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/514978","article-title":"Disseminated adenovirus disease in immunocompromised and immunocompetent children","volume":"27","author":"Munoz","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"Fso412","DOI":"10.2144\/fsoa-2019-0072","article-title":"Disseminated adenovirus infection in a patient with a hematologic malignancy: A case report and literature review","volume":"5","author":"Takamatsu","year":"2019","journal-title":"Future Sci. OA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1128\/CMR.00052-07","article-title":"Adenoviruses in immunocompromised hosts","volume":"21","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/tid.12022","article-title":"European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: Summary of ECIL-4 (2011)","volume":"14","author":"Feuchtinger","year":"2012","journal-title":"Transpl. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/s41409-024-02361-9","article-title":"Adenovirus infections after allogeneic hematopoietic cell transplantation in children and adults: A study from the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation","volume":"59","author":"Styczynski","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/323464a0","article-title":"A novel selective broad-spectrum anti-DNA virus agent","volume":"323","author":"Rosenberg","year":"1986","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0166-3542(87)80004-9","article-title":"Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines","volume":"8","author":"Sakuma","year":"1987","journal-title":"Antivir. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0002-9394(14)71233-4","article-title":"Phase I\/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome","volume":"119","author":"Kirsch","year":"1995","journal-title":"Am. J. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/1060028019897896","article-title":"Intravesicular Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis Following Hematopoietic Stem Cell Transplantation","volume":"54","author":"Tooker","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105995","DOI":"10.1016\/j.antiviral.2024.105995","article-title":"Treatment efficacy of cidofovir and brincidofovir against clade II Monkeypox virus isolates","volume":"231","author":"Sloan","year":"2024","journal-title":"Antivir. Res."},{"key":"ref_26","unstructured":"CDC (2025, February 03). Available online: https:\/\/www.cdc.gov\/smallpox\/treatment\/index.html."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1128\/AAC.41.8.1846","article-title":"Fanconi syndrome associated with cidofovir therapy","volume":"41","author":"Vittecoq","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"(1997). Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ann. Intern. Med., 126, 264\u2013274.","DOI":"10.7326\/0003-4819-126-4-199702150-00002"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-126-4-199702150-00001","article-title":"Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial","volume":"126","author":"Lalezari","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0090-9556(25)07424-0","article-title":"Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats","volume":"24","author":"Cundy","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1128\/AAC.35.4.701","article-title":"Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice","volume":"35","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/toxsci\/44.2.97","article-title":"Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys","volume":"44","author":"Lacy","year":"1998","journal-title":"Toxicol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0090-9556(25)07349-0","article-title":"Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits","volume":"24","author":"Cundy","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0166-3542(95)00962-0","article-title":"Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model","volume":"31","author":"Stevenson","year":"1996","journal-title":"Antivir. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1086\/498151","article-title":"Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients","volume":"41","author":"Muller","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/135965350501000204","article-title":"In vitro susceptibility of adenovirus to antiviral drugs is species-dependent","volume":"10","author":"Morfin","year":"2005","journal-title":"Antivir. Ther."},{"key":"ref_37","first-page":"2774","article-title":"Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir","volume":"37","author":"Gordon","year":"1996","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1086\/517647","article-title":"Adenovirus cholecystitis in a patient with AIDS","volume":"26","author":"Hedderwick","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1086\/517222","article-title":"Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient","volume":"28","author":"Ribaud","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bmt.1702820","article-title":"Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children","volume":"27","author":"Legrand","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1053\/bbmt.2001.v7.pm11529489","article-title":"Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation","volume":"7","author":"Hoffman","year":"2001","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1399-3062.2009.00391.x","article-title":"Safety and tolerability of cidofovir in high-risk pediatric patients","volume":"11","author":"Bhadri","year":"2009","journal-title":"Transpl. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e13231","DOI":"10.1111\/petr.13231","article-title":"Virologic response with 2 different cidofovir dosing regimens for preemptive treatment of adenovirus DNAemia in pediatric solid organ transplant recipients","volume":"22","author":"Lorica","year":"2018","journal-title":"Pediatr. Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/10600280231176135","article-title":"Cidofovir for Viral Infections in Immunocompromised Children: Guidance on Dosing, Safety, Efficacy, and a Review of the Literature","volume":"58","author":"Riggsbee","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1093\/jac\/dkab259","article-title":"Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: A retrospective multicentre cohort study","volume":"76","author":"Stern","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1399-3046.2007.00851.x","article-title":"High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy","volume":"12","author":"Anderson","year":"2008","journal-title":"Pediatr. Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bmt.1704682","article-title":"Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients","volume":"34","author":"Nagafuji","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2019.01.008","article-title":"In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review","volume":"163","author":"Chemaly","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1399-3062.2006.00184.x","article-title":"Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: High mortality in the era of cidofovir","volume":"9","author":"Symeonidis","year":"2007","journal-title":"Transpl. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.11279","article-title":"Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcome","volume":"92","author":"Robin","year":"2007","journal-title":"Haematologica"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bbmt.2014.10.012","article-title":"The effect of cidofovir on adenovirus plasma DNA levels in stem cell transplantation recipients without T cell reconstitution","volume":"21","author":"Lugthart","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1097\/01.tp.0000209195.95115.8e","article-title":"Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients","volume":"81","author":"Yusuf","year":"2006","journal-title":"Transplantation"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/TP.0000000000003988","article-title":"Adenovirus Infection and Transplantation","volume":"106","author":"Cathro","year":"2022","journal-title":"Transplantation"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1086\/427513","article-title":"Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients","volume":"191","author":"Heemskerk","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/bloodadvances.2021004456","article-title":"Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted","volume":"5","author":"Rubinstein","year":"2021","journal-title":"Blood Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00277-012-1440-3","article-title":"Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation","volume":"91","author":"Taniguchi","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s41409-018-0421-0","article-title":"A survey on incidence and management of adenovirus infection after allogeneic HSCT","volume":"54","author":"Cesaro","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_58","first-page":"2062","article-title":"How I prevent viral reactivation in high-risk patients","volume":"141","author":"Dadwal","year":"2023","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e1980","DOI":"10.1002\/rmv.1980","article-title":"Management of adenovirus infection in patients after haematopoietic stem cell transplantation: State-of-the-art and real-life current approach: A position statement on behalf of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation","volume":"28","author":"Hiwarkar","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3390\/v2122740","article-title":"Development of CMX001 for the Treatment of Poxvirus Infections","volume":"2","author":"Lanier","year":"2010","journal-title":"Viruses"},{"key":"ref_61","unstructured":"Chimerix (2025, March 19). Available online: https:\/\/www.congress.gov\/115\/meeting\/house\/108389\/witnesses\/HHRG-115-IF14-Wstate-BerreyM-20180606.pdf."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3390\/v2102213","article-title":"Synthesis and early development of hexadecyloxypropylcidofovir: An oral antipoxvirus nucleoside phosphonate","volume":"2","author":"Hostetler","year":"2010","journal-title":"Viruses"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0166-3542(03)00110-4","article-title":"Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney","volume":"59","author":"Ciesla","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/AAC.46.4.991-995.2002","article-title":"Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir","volume":"46","author":"Kern","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","article-title":"Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro","volume":"46","author":"Beadle","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1124\/mol.63.3.678","article-title":"Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism","volume":"63","author":"Aldern","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"ref_67","unstructured":"ASPR (2025, March 05). Available online: https:\/\/aspr.hhs.gov\/SNS\/Pages\/Mpox.aspx."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/426831","article-title":"Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: Activity against adenovirus replication in vitro","volume":"191","author":"Hartline","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1073\/pnas.0800200105","article-title":"Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model","volume":"105","author":"Toth","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.bbmt.2011.09.007","article-title":"Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients","volume":"18","author":"Florescu","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jcv.2010.10.016","article-title":"Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001","volume":"50","author":"Paolino","year":"2011","journal-title":"J. Clin. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/tid.12582","article-title":"Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation","volume":"18","author":"Voigt","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jcv.2017.09.013","article-title":"Disseminated adenovirus infection after allogeneic stem cell transplant and the potential role of brincidofovir\u2014Case series and 10 year experience of management in an adult transplant cohort","volume":"96","author":"Ramsay","year":"2017","journal-title":"J. Clin. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1097\/MPH.0000000000001480","article-title":"Brincidofovir as a Salvage Therapy in Controlling Adenoviremia in Pediatric Recipients of Hematopoietic Stem Cell Transplant","volume":"41","author":"Meena","year":"2019","journal-title":"J. Pediatr. Hematol.\/Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/phar.2094","article-title":"Brincidofovir as Salvage Therapy for Adenovirus Disease in Intestinal Transplant Recipients","volume":"38","author":"Sulejmani","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e13769","DOI":"10.1111\/petr.13769","article-title":"Brincidofovir for the treatment of human adenovirus infection in pediatric solid organ transplant recipients: A case series","volume":"24","author":"Londeree","year":"2020","journal-title":"Pediatr. Transplant."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2016-11-749721","article-title":"Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant","volume":"129","author":"Hiwarkar","year":"2017","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e13505","DOI":"10.1111\/tid.13505","article-title":"Risks and outcomes of adenovirus disease in pediatric hematopoietic stem cell transplant recipients-Comparison of current antiviral treatment options","volume":"23","author":"Thomas","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1038\/s41409-021-01285-y","article-title":"Safety and efficacy of brincidofovir for Adenovirus infection in children receiving allogeneic stem cell transplantation: An AIEOP retrospective analyses","volume":"56","author":"Perruccio","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.bbmt.2016.12.621","article-title":"Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial","volume":"23","author":"Grimley","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.jtct.2023.12.144","article-title":"Preliminary Results of a Phase 2a Clinical Trial to Evaluate Safety, Tolerability and Antiviral Activity of Intravenous Brincidofovir (BCV IV) in Immunocompromised Patients with Adenovirus Infection","volume":"30","author":"Grimley","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide","volume":"177","author":"Sidwell","year":"1972","journal-title":"Science"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/jm00281a014","article-title":"Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides","volume":"15","author":"Witkowski","year":"1972","journal-title":"J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev. Med. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.eimc.2018.05.008","article-title":"Use of ribavirin in viruses other than hepatitis C. A review of the evidence","volume":"37","author":"Membrillo","year":"2019","journal-title":"Enfermedades Infecc. Microbiol. Clin. (Engl. Ed.)"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3810\/pgm.2009.05.2014","article-title":"Original research: Intravenous ribavirin\u2014Review of the FDA\u2019s Emergency Investigational New Drug Database (1997\u20132008) and literature review","volume":"121","author":"Riner","year":"2009","journal-title":"Postgrad. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0041-008X(84)90139-X","article-title":"Hematological and bone marrow effects of ribavirin in rhesus monkeys","volume":"74","author":"Canonico","year":"1984","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2893.2004.00490.x","article-title":"Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection","volume":"11","author":"Sulkowski","year":"2004","journal-title":"J. Viral. Hepat."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1086\/376911","article-title":"Anemia in the treatment of hepatitis C virus infection","volume":"37","author":"Sulkowski","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/tera.1420170117","article-title":"Teratogenic effects of ribavirin on hamster and rat embryos","volume":"17","author":"Ferm","year":"1978","journal-title":"Teratology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40264-017-0566-6","article-title":"The Ribavirin Pregnancy Registry: An interim analysis of potential teratogenicity at the mid-point of enrollment","volume":"40","author":"Sinclair","year":"2017","journal-title":"Drug Saf."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/0018578719836646","article-title":"The use of aerosolized ribavirin in respiratory syncytial virus lower respiratory tract infections in adult immunocompromised patients: A systematic review","volume":"55","author":"Avery","year":"2020","journal-title":"Hosp. Pharm."},{"key":"ref_93","unstructured":"(2019). Virazole (Ribavirin for Inhalation Solution) [Package Insert], Bausch Health."},{"key":"ref_94","first-page":"106","article-title":"The effect of purine and pyrimidine analogues and virazole on adenovirus replication","volume":"19","author":"Scheffler","year":"1975","journal-title":"Acta Virol."},{"key":"ref_95","first-page":"121","article-title":"Antiviral chemotherapy: In vitro activity of ribavirin on DNA and RNA viruses","volume":"24","author":"Lagrota","year":"1982","journal-title":"Rev. Latinoam. Microbiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S0140-6736(85)90941-9","article-title":"Nebulised ribavirin for adenovirus pneumonia","volume":"2","author":"Buchdahl","year":"1985","journal-title":"Lancet"},{"key":"ref_97","first-page":"247","article-title":"Intravenous ribavirin therapy for adenovirus cystitis after allogeneic bone marrow transplantation","volume":"7","author":"Cassano","year":"1991","journal-title":"Bone Marrow Transplant."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00005-011-0148-8","article-title":"Disseminated adenovirus disease in immunocompromised patient successfully treated with oral ribavirin: A case report","volume":"59","author":"Ulrych","year":"2011","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_99","first-page":"215","article-title":"Adenovirus pneumonia treated with Cidofovir in an immunocompetent high school senior","volume":"26","author":"Yoon","year":"2019","journal-title":"Respir. Med. Case Rep."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Lin, L., Tang, M., Li, D., Fei, H., and Zhang, H. (2024). Combined intravenous ribavirin and recombinant human interferon \u03b11b aerosol inhalation for adenovirus pneumonia with plastic bronchitis in children: A case report and review of literature. Front. Pediatr., 12.","DOI":"10.3389\/fped.2024.1295133"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.thj.6200358","article-title":"Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and\/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell transplants","volume":"5","author":"Schleuning","year":"2004","journal-title":"Hematol. J."},{"key":"ref_102","first-page":"663","article-title":"Failure of ribavirin to clear adenovirus infections in T cell-depleted allogeneic bone marrow transplantation","volume":"14","author":"Hromas","year":"1994","journal-title":"Bone Marrow Transplant."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/319984","article-title":"Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"32","author":"Bordigoni","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1086\/319352","article-title":"Adenovirus infections in adult recipients of blood and marrow transplants","volume":"32","author":"Champlin","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1086\/420817","article-title":"Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection","volume":"38","author":"Lankester","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_106","first-page":"409","article-title":"Severe adenoviral nephritis following bone marrow transplantation: Successful treatment with intravenous ribavirin","volume":"12","author":"Liles","year":"1993","journal-title":"Bone Marrow Transplant."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0022-5347(17)36149-9","article-title":"Adenovirus-associated hemorrhagic cystitis treated with intravenous ribavirin","volume":"149","author":"Murphy","year":"1993","journal-title":"J. Urol."},{"key":"ref_108","first-page":"651","article-title":"Adenovirus-associated haemorrhagic cystitis after bone marrow transplantation successfully treated with intravenous ribavirin","volume":"15","author":"Jurado","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"ref_109","first-page":"110","article-title":"Intravenous ribavirin therapy for adenovirus gastroenteritis after bone marrow transplantation","volume":"21","author":"Kapelushnik","year":"1995","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/00007890-199503270-00028","article-title":"Recovery from adenovirus pneumonia in a severe combined immunodeficiency patient treated with intravenous ribavirin","volume":"59","author":"Wulffraat","year":"1995","journal-title":"Transplantation"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0163-4453(98)80021-2","article-title":"Failure of intravenous ribavirin in the treatment of invasive adenovirus infection following allogeneic bone marrow transplantation: A case report","volume":"36","author":"Mann","year":"1998","journal-title":"J. Infect."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/sj.bmt.1701788","article-title":"Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: Failure of intravenous ribavirin therapy","volume":"23","author":"Chakrabarti","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bmt.1701563","article-title":"Adenovirus infection after pediatric bone marrow transplantation","volume":"23","author":"Hale","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1086\/313514","article-title":"Adenovirus infections in hematopoietic stem cell transplant recipients","volume":"29","author":"Howard","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/sj.bmt.1702040","article-title":"Intravesicular instillation of E-aminocaproic acid for patients with adenovirus-induced hemorrhagic cystitis","volume":"24","author":"Lakhani","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/sj.bmt.1702195","article-title":"Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors","volume":"25","author":"Miyamura","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF02982557","article-title":"Lethal adenovirus infection in a patient who had undergone nonmyeloablative stem cell transplantation","volume":"74","author":"Ikegame","year":"2001","journal-title":"Int. J. Hematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1542\/peds.110.1.e9","article-title":"Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children","volume":"110","author":"Gavin","year":"2002","journal-title":"Pediatrics"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0022-3476(97)70246-4","article-title":"Intravenous ribavirin therapy in a neonate with disseminated adenovirus infection undergoing extracorporeal membrane oxygenation: Pharmacokinetics and clearance by hemofiltration","volume":"130","author":"Aebi","year":"1997","journal-title":"J. Pediatr."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1399-3062.2010.00528.x","article-title":"Poor outcome of adenovirus infections in adult hematopoietic stem cell transplant patients with sustained adenovirus viremia","volume":"12","author":"Omar","year":"2010","journal-title":"Transpl. Infect. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s12288-015-0530-5","article-title":"A Rare Case of Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplant Patient","volume":"32","author":"Sahu","year":"2016","journal-title":"Indian. J. Hematol. Blood Transfus."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/jha2.956","article-title":"Overcoming post-transplant graft failure and adenovirus infection in a patient with FLT3-TKD-mutated mixed-phenotype acute leukemia: A case report","volume":"5","author":"Takada","year":"2024","journal-title":"EJHaem"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/ndt\/gfg365","article-title":"Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: Successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin","volume":"18","author":"Emovon","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.transproceed.2004.10.090","article-title":"Hemorrhagic adenovirus cystitis after renal transplantation","volume":"36","author":"Hofland","year":"2004","journal-title":"Transplant. Proc."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1399-0012.2009.01005.x","article-title":"A case of acute rejection with adenovirus infection after ABO-incompatible kidney transplantation","volume":"23","author":"Komiya","year":"2009","journal-title":"Clin. Transplant."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.transproceed.2014.11.054","article-title":"Successful treatment of disseminated adenovirus infection with ribavirin and intravenous immunoglobulin in an adult renal transplant recipient: A case report","volume":"47","author":"Park","year":"2015","journal-title":"Transplant. Proc."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/135965350901400110","article-title":"Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone","volume":"14","author":"Morfin","year":"2009","journal-title":"Antivir. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.antiviral.2006.03.009","article-title":"A rapid quantitative PCR-based assay for testing antiviral agents against human adenoviruses demonstrates type specific differences in ribavirin activity","volume":"72","author":"Stock","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1574-6968.1988.tb02753.x","article-title":"The susceptibillity of adenovirus infeection to the anti-cytomegalovirus drug, ganciclovir (DHPG)","volume":"49","author":"Taylor","year":"1988","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00003226-199409000-00011","article-title":"Activity of ganciclovir against human adenovirus type-5 infection in cell culture and cotton rat eyes","volume":"13","author":"Trousdale","year":"1994","journal-title":"Cornea"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1128\/AAC.03860-14","article-title":"Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters","volume":"58","author":"Ying","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/v7031409","article-title":"Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters","volume":"7","author":"Toth","year":"2015","journal-title":"Viruses"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s15010-020-01484-7","article-title":"Adenovirus diseases: A systematic review and meta-analysis of 228 case reports","volume":"49","author":"Gu","year":"2021","journal-title":"Infection"},{"key":"ref_134","first-page":"295","article-title":"Adenovirus infection in a renal transplant patient","volume":"24","author":"Nyberg","year":"1992","journal-title":"Transplant. Proc."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bmt.1700997","article-title":"Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir","volume":"20","author":"Chen","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0002-9343(97)85997-9","article-title":"Treatment with ganciclovir of adenovirus pneumonia in a cardiac transplant patient","volume":"103","author":"Duggan","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbmt.2007.12.001","article-title":"Disseminated adenovirus disease by multiple adenovirus serotypes following allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Suzuki","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1399-3046.2008.01027.x","article-title":"Urinary excretion of ganciclovir contributes to improvement of adenovirus-associated hemorrhagic cystitis after allogeneic bone marrow transplantation","volume":"13","author":"Nakazawa","year":"2009","journal-title":"Pediatr. Transplant."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2169\/internalmedicine.53.1192","article-title":"Adenovirus pneumonia presenting with nodular shadows on chest X-ray in two unrelated allogeneic bone marrow transplant recipients","volume":"53","author":"Mochizuki","year":"2014","journal-title":"Intern. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jiac.2018.11.011","article-title":"Disseminated adenovirus infection in a patient with relapsed refractory multiple myeloma undergoing autologous stem cell transplantation and pomalidomide\/dexamethasone as salvage regimens","volume":"25","author":"Yasuda","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1111\/j.1600-6143.2005.00945.x","article-title":"Adenovirus tubulointerstitial nephritis presenting as a renal allograft space occupying lesion","volume":"5","author":"Lim","year":"2005","journal-title":"Am. J. Transplant."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1399-3062.2010.00572.x","article-title":"Donor-transmitted adenovirus infection causing kidney allograft nephritis and graft loss","volume":"13","author":"Kozlowski","year":"2011","journal-title":"Transpl. Infect. Dis."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/tid.12519","article-title":"Clinical characteristics and outcomes of adenovirus infection of the urinary tract after renal transplantation","volume":"18","author":"Nanmoku","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.kint.2016.07.003","article-title":"The Case|Unexplained fever and acute kidney injury in a kidney transplant patient","volume":"90","author":"Paula","year":"2016","journal-title":"Kidney Int."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.kint.2017.03.016","article-title":"Adenovirus pyelonephritis in the late posttransplant period","volume":"92","author":"Muglia","year":"2017","journal-title":"Kidney Int."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.nefroe.2019.02.003","article-title":"Adenovirus infection-A rare cause of interstitial nephritis in kidney transplant","volume":"39","author":"Moreira","year":"2019","journal-title":"Nefrologia (Engl. Ed.)"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"368","DOI":"10.7326\/0003-4819-103-3-368","article-title":"Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia","volume":"103","author":"Shepp","year":"1985","journal-title":"Ann. Intern. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbmt.2003.11.001","article-title":"Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab","volume":"10","author":"Avivi","year":"2004","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1083-8791(03)00102-2","article-title":"Adenovirus infection in hematopoietic stem cell transplantation: Effect of ganciclovir and impact on survival","volume":"9","author":"Bruno","year":"2003","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/1469-0691.12222","article-title":"Risk factors of ganciclovir-related neutropenia after allogeneic stem cell transplantation: A retrospective monocentre study on 547 patients","volume":"20","author":"Venton","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/sj.bmt.1700923","article-title":"Vidarabine therapy for virus-associated cystitis after allogeneic bone marrow transplantation","volume":"20","author":"Kawakami","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"ref_153","first-page":"853","article-title":"Successful vidarabine therapy for adenovirus type 11-associated acute hemorrhagic cystitis after allogeneic bone marrow transplantation","volume":"14","author":"Kitabayashi","year":"1994","journal-title":"Bone Marrow Transplant."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.bmt.1702129","article-title":"Sequential vidarabine infusion in the treatment of polyoma virus-associated acute haemorrhagic cystitis late after allogeneic bone marrow transplantation","volume":"25","author":"Vianelli","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/095632020401500507","article-title":"Therapeutic basis of vidarabine on adenovirus-induced haemorrhagic cystitis","volume":"15","author":"Kurosaki","year":"2004","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Saha, B., and Parks, R.J. (2020). Recent Advances in Novel Antiviral Therapies against Human Adenovirus. Microorganisms, 8.","DOI":"10.3390\/microorganisms8091284"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"105034","DOI":"10.1016\/j.antiviral.2021.105034","article-title":"Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies","volume":"188","author":"Dodge","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Wen, X., Zhang, L., Zhao, S., Liu, Q., Guan, W., Wu, J., Zhang, Q., Wen, H., and Huang, W. (2021). High-Throughput Screening and Identification of Human Adenovirus Type 5 Inhibitors. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.767578"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Liu, M., Jiang, L., Cao, W., Wu, J., and Chen, X. (2022). Identification of Inhibitors and Drug Targets for Human Adenovirus Infections. Viruses, 14.","DOI":"10.3390\/v14050959"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"105431","DOI":"10.1016\/j.antiviral.2022.105431","article-title":"Filociclovir is a potent inhibitor of human adenovirus F41","volume":"208","author":"Tollefson","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/jmv.25468","article-title":"Absolute lymphocyte count and human adenovirus-specific T-cell immune restoration of human adenovirus infection after kidney transplantation","volume":"91","author":"Bruminhent","year":"2019","journal-title":"J. Med. Virol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood.V84.5.1689.1689","article-title":"Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation","volume":"84","author":"Hromas","year":"1994","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminhematol.2022.12.002","article-title":"Applications of virus-specific T cell therapies post-BMT","volume":"60","author":"Motta","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","article-title":"Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation","volume":"114","author":"Leen","year":"2009","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood-2014-06-573725","article-title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT","volume":"125","author":"Feucht","year":"2015","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jaci.2016.03.032","article-title":"Specific T cells for the treatment of cytomegalovirus and\/or adenovirus in the context of hematopoietic stem cell transplantation","volume":"138","author":"Creidy","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jcyt.2018.03.040","article-title":"Multicenter phase 1\/2 application of adenovirus-specific T cells in high-risk pediatric patients after allogeneic stem cell transplantation","volume":"20","author":"Ip","year":"2018","journal-title":"Cytotherapy"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/bloodadvances.2019000201","article-title":"Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients","volume":"3","author":"Abraham","year":"2019","journal-title":"Blood Adv."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1182\/bloodadvances.2021006309","article-title":"Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant","volume":"6","author":"Rubinstein","year":"2022","journal-title":"Blood Adv."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting","volume":"29","author":"Pfeiffer","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1038\/s41467-024-47057-2","article-title":"Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): A two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment","volume":"15","author":"Keller","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-017-0469-0","article-title":"Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: A successful phase I\/II multicenter clinical trial","volume":"10","author":"Qian","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jtct.2023.01.027","article-title":"Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults","volume":"29","author":"Galletta","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.ajt.2024.05.019","article-title":"Virus-specific T cell therapy to treat refractory viral infections in solid organ transplant recipients","volume":"24","author":"Schweitzer","year":"2024","journal-title":"Am. J. Transplant."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for \u2018off the shelf\u2019 adoptive therapy of refractory infections","volume":"51","author":"Prockop","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1111\/trf.12754","article-title":"A registry of HLA-typed donors for production of virus-specific CD4 and CD8 T lymphocytes for adoptive reconstitution of immune-compromised patients","volume":"54","author":"Ivaldi","year":"2014","journal-title":"Transfusion"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1182\/bloodadvances.2023011562","article-title":"Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients","volume":"8","author":"Dadwal","year":"2024","journal-title":"Blood Adv."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ymthe.2020.06.002","article-title":"CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation","volume":"28","author":"Kaeuferle","year":"2020","journal-title":"Mol. Ther."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/5\/599\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:20:00Z","timestamp":1760030400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/5\/599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":184,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["v17050599"],"URL":"https:\/\/doi.org\/10.3390\/v17050599","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]}}}